Rani Therapeutics Holdings Inc Cl A (RANI)

$1.13 -0.02 (-1.74%)
Market Cap 144.60M
Revenue (ttm) 1.03M
Net Income (ttm) -30.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,914.56%
Debt to Equity Ratio -1.88
Volume 906,700
Avg Vol 1,004,658
Day's Range N/A - N/A
Shares Out 121.51M
Stochastic %K 10%
Beta 0.39
Analysts Strong Sell
Price Target $8.00

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 457 3700
Address:
2051 Ringwood Avenue, San Jose, United States
Oleks14
Oleks14 Mar. 21 at 3:52 AM
$RANI This is a whole technology, not just a standalone pill. See the difference
0 · Reply
APRadek
APRadek Mar. 20 at 5:01 PM
$RANI realisticly any predictions before earnings, business update?
1 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 12:28 PM
🐉 $RANI CALL — DragonAlgo® Signal Contract: RANI CALL Expiry: 2026-03-20 | Strike: $1.50 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com
0 · Reply
Hakapeszi
Hakapeszi Mar. 20 at 6:13 AM
$RANI report on 2025 and business update next Thursday. https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-report-fourth-quarter-and-full-year-2025
0 · Reply
French_Vibe
French_Vibe Mar. 19 at 7:56 PM
$RANI Bought few shares at $1.13 (pure speculation).
1 · Reply
Bakhm
Bakhm Mar. 19 at 2:49 PM
$RANI under $1 again ?
0 · Reply
JaJadingdong1
JaJadingdong1 Mar. 19 at 2:48 PM
$RANI I added a ton yesterday. I believe
0 · Reply
wavw
wavw Mar. 19 at 2:15 PM
$RANI looks like shorts are covering…
0 · Reply
kellymone2
kellymone2 Mar. 19 at 12:48 PM
$RANI joined @ 1,19$
0 · Reply
Tooneyman
Tooneyman Mar. 19 at 1:08 AM
$RANI be patient .... It'll go back up soon. Good time to buy more.
0 · Reply
Latest News on RANI
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Mar 19, 2026, 4:05 PM EDT - 2 days ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Jan 28, 2026, 7:00 AM EST - 7 weeks ago

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Jan 8, 2026, 7:00 AM EST - 2 months ago

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 4 months ago

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Nov 6, 2025, 4:30 PM EST - 4 months ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 30, 2025, 8:00 AM EDT - 5 months ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:05 PM EDT - 5 months ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 23, 2025, 4:01 PM EDT - 5 months ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai

Oct 20, 2025, 2:20 PM EDT - 5 months ago

Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 5 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:48 AM EDT - 5 months ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:31 AM EDT - 5 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Oct 17, 2025, 7:30 AM EDT - 5 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 15, 2025, 9:00 AM EDT - 8 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Jul 14, 2025, 5:00 AM EDT - 8 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025, 8:00 AM EDT - 10 months ago

Rani Therapeutics Announces Research Agreement with Chugai

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025, 4:05 PM EDT - 11 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:15 PM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025, 6:00 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Rani Therapeutics to Participate in September Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in September Investor Conferences

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics to Participate in August Investor Conferences

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in August Investor Conferences

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Rani Therapeutics to Participate in May Investor Conferences

May 14, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Participate in May Investor Conferences

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

May 6, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 7:05 PM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Mar 15, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Nov 8, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 19, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Sep 19, 2023, 6:36 AM EDT - 2 years ago

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Sep 7, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 21, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 8, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 5, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Rani Therapeutics to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 31, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 24, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

Oleks14
Oleks14 Mar. 21 at 3:52 AM
$RANI This is a whole technology, not just a standalone pill. See the difference
0 · Reply
APRadek
APRadek Mar. 20 at 5:01 PM
$RANI realisticly any predictions before earnings, business update?
1 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 12:28 PM
🐉 $RANI CALL — DragonAlgo® Signal Contract: RANI CALL Expiry: 2026-03-20 | Strike: $1.50 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com
0 · Reply
Hakapeszi
Hakapeszi Mar. 20 at 6:13 AM
$RANI report on 2025 and business update next Thursday. https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-report-fourth-quarter-and-full-year-2025
0 · Reply
French_Vibe
French_Vibe Mar. 19 at 7:56 PM
$RANI Bought few shares at $1.13 (pure speculation).
1 · Reply
Bakhm
Bakhm Mar. 19 at 2:49 PM
$RANI under $1 again ?
0 · Reply
JaJadingdong1
JaJadingdong1 Mar. 19 at 2:48 PM
$RANI I added a ton yesterday. I believe
0 · Reply
wavw
wavw Mar. 19 at 2:15 PM
$RANI looks like shorts are covering…
0 · Reply
kellymone2
kellymone2 Mar. 19 at 12:48 PM
$RANI joined @ 1,19$
0 · Reply
Tooneyman
Tooneyman Mar. 19 at 1:08 AM
$RANI be patient .... It'll go back up soon. Good time to buy more.
0 · Reply
BBTAAPL
BBTAAPL Mar. 18 at 7:03 PM
$RANI added way more
0 · Reply
Bakhm
Bakhm Mar. 18 at 6:46 PM
$RANI When are the next news ?
1 · Reply
Hakapeszi
Hakapeszi Mar. 18 at 6:38 PM
$RANI added more
0 · Reply
Bakhm
Bakhm Mar. 18 at 6:38 PM
$RANI Looks like crap, as usual
0 · Reply
APRadek
APRadek Mar. 18 at 3:34 PM
$RANI a lot inflow, people doing DCA
1 · Reply
Tooneyman
Tooneyman Mar. 18 at 2:47 PM
$RANI hold
0 · Reply
JaJadingdong1
JaJadingdong1 Mar. 18 at 2:20 PM
$RANI Buy
0 · Reply
lisaparsons
lisaparsons Mar. 18 at 2:07 PM
$RANI what now folks?
3 · Reply
BBTAAPL
BBTAAPL Mar. 18 at 2:03 PM
$RANI I’ll never understand why there is so much OI on the 4.17 $2.5/$5 C. If anybody knows please share
1 · Reply
BBTAAPL
BBTAAPL Mar. 18 at 2:02 PM
$RANI what the actual hell, fuck this company
0 · Reply
wavw
wavw Mar. 18 at 1:50 PM
$RANI why?
0 · Reply
llchen1204
llchen1204 Mar. 17 at 5:54 PM
$RANI
0 · Reply